Since 1992, when FDA issued its
Statement of Policy: Foods Derived from New Plant Varieties (57 FR
22984, May 29, 1992), the Food and Drug Administration (FDA) has
encouraged developers of new plant varieties, including those
varieties that are developed through biotechnology, to consult with
FDA early in the development process to discuss possible scientific
and regulatory issues that might arise. The guidance titled,
"Recommendations for the Early Food Safety Evaluation of New
Non-Pesticidal Proteins Produced by New Plant Varieties Intended
for Food Use," continues to foster early communication by
encouraging developers to submit to FDA their evaluation of the
food safety of their new protein. Such communication helps to
ensure that any potential food safety issues regarding a new
protein in a new plant variety are resolved early in development,
prior to any possible inadvertent introduction into the food supply
of material from that plant variety. FDA believes that any food
safety concern related to such material entering the food supply
would be limited to the potential that a new protein in food from
the plant variety could cause an allergic reaction in susceptible
individuals or could be a toxin.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.